FIELD: biotechnology.
SUBSTANCE: described is a group of inventions comprising a conjugate of an anti-B7-H4 antibody and a drug for transfer of a cytotoxic drug into cancer cells, method of producing an antibody conjugate, a pharmaceutical composition for treating a disease associated with human B7-H4, use of the conjugate of the antibody to B7-H4 or a pharmaceutical composition for preparing a drug for treating a disease associated with human B7-H4. In one of the embodiments, the conjugate is represented by the general formula
,
where D is a cytotoxic drug.
EFFECT: invention extends the range of products for treating diseases associated with human B7-H4.
18 cl, 4 dwg, 9 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-BCMA ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF | 2020 |
|
RU2819660C2 |
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
| ANTIBODY AGAINST B7-H3, ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL USE | 2018 |
|
RU2765306C2 |
| ANTI-CLAUDIN 18.2 ANTIBODY AND USE THEREOF | 2020 |
|
RU2822550C2 |
| CONJUGATE OF ANTI-CLAUDIN ANTIBODY AND MEDICINAL AGENT AND PHARMACEUTICAL USE THEREOF | 2020 |
|
RU2826119C1 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
| ANTIBODY TO TIGIT AND ITS USE | 2019 |
|
RU2786434C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| ANTIBODY TO CD40, ITS ANTIGENE-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2779128C2 |
| ANTIBODY-DRUG CONJUGATE, INTERMEDIATE FOR ITS PRODUCTION, METHOD OF ITS PRODUCTION AND ITS USE | 2020 |
|
RU2800137C1 |
